Modulation of drug and radiation resistant genes

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 5989908
SERIAL NO

08793878

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The effects of suppressing c-fos oncogene expression on drug or radiation resistant mammalian cells are described. A2780S human ovarian carcinoma cells with resistance to actinomycin D were isolated and the resultant A2780AD cells exhibited the MDR phenotype. A hammerhead ribozyme designed to cleave fos RNA cloned into the pMAMneo plasmid was transfected into A2780AD cells. Induction of the ribozyme resulted in decreased expression of c-fos, followed by that of mdr-1, c-jun, and p53. Reversal of the MDR phenotype by the anti-mdr ribozyme occurred one-fourth as rapidly as that induced by the anti-fos ribozyme. These studies demonstrate the primacy of the c-fos oncogene in maintaining the resistant phenotype in human cancer cells. Thus, down regulation of fos/jun will make resistant cancer cells more sensitive to conventional treatment, i.e., cancer chemotherapeutic agents and/or radiation.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
CITY OF HOPE1500 EAST DUARTE ROAD DUARTE CA 91010-0269

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Scanlon, Kevin J Pasadena, CA 9 117

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation